• Home
  •  / Proteon Therapeutics

Proteon Therapeutics

OverviewSuggest Edit

Proteon Therapeutics is a late-stage biopharmaceutical company committed to improving the lives of patients and families affected by kidney and vascular diseases. The Company is developing potentially transformative solutions to address some of the most urgent needs of patients with chronic kidney disease requiring hemodialysis and peripheral artery disease with the goal of redefining how these diseases are treated. Proteon's lead product candidate, Vonapanitase, is a first-in-class, phase 3 investigational drug designed to treat vessel injury that leads to blood vessel blockage and reduced blood flow. These complications can prevent a patient from undergoing life-saving hemodialysis and result in corrective procedures, excess costs and patient trauma.

TypePublic
Founded2001
HQWaltham, MA, USMap
Websiteproteontherapeutics.com
View Jobs

Recent NewsAll News

Latest Updates

Employees (est.) (Mar 2019)17(+7%)
Revenue (FY, 2014)$2.9 M
Share Price (Jan 2020)$33.4 (+5040%)
Cybersecurity ratingBMore

Key People/Management at Proteon Therapeutics

Timothy Noyes

Timothy Noyes

President and Chief Executive Officer
George Eldridge

George Eldridge

Senior Vice President and Chief Financial Officer
Show more

Proteon Therapeutics Office Locations

Proteon Therapeutics has an office in Waltham
Waltham, MA, US (HQ)
200 West St
Show all (1)

Proteon Therapeutics Financials and Metrics

Proteon Therapeutics Revenue

Proteon Therapeutics's revenue was reported to be $2.95 m in FY, 2014
USD

Net income (Q1, 2020)

(10.1m)

EBIT (Q1, 2020)

(10.2m)

Market capitalization (9-Jan-2020)

18.5m

Closing stock price (9-Jan-2020)

33.4

Cash (31-Mar-2020)

36.1m

EV

(15.8m)
Proteon Therapeutics's current market capitalization is $18.5 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

2.9m

General and administrative expense

4.1m8.5m9.8m8.7m9.5m8.8m

R&D expense

6.4m12.4m18.9m21.7m11.8m6.4m

Operating expense total

10.5m20.9m28.7m30.4m21.4m15.3m
Quarterly
USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Revenue

2.9m

General and administrative expense

1.0m2.0m1.9m2.0m2.5m2.6m2.3m2.2m2.1m2.0m2.3m2.2m2.3m2.6m3.3m1.4m7.1m

R&D expense

1.8m2.6m3.1m3.1m4.3m5.2m4.8m4.2m3.9m10.3m4.1m2.8m2.4m4.0m2.1m206.0k3.1m

Operating expense total

2.8m4.6m5.0m5.1m6.8m7.9m7.2m6.5m6.0m12.3m6.4m5.0m4.6m6.6m5.4m1.6m10.2m
show all
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

68.8m40.0m36.4m21.2m19.4m6.2m

Accounts Receivable

1.7b

Prepaid Expenses

1.0m1.3m1.3m1.4m744.0k

Current Assets

84.6m66.6m42.8m43.5m23.2m7.0m
Quarterly
USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Cash

3.2m9.8m16.8m36.0m24.1m34.2m26.7m34.1m18.4m20.0m25.4m12.5m18.2m16.8m10.8m9.3m36.1m

Prepaid Expenses

168.0k1.2m1.1m829.0k1.1m1.2m1.7m1.3m1.3m554.0k1.2m1.1m871.0k1.0m614.0k277.0k3.6m

Current Assets

21.9m80.7m75.8m71.4m60.4m54.9m48.7m35.4m33.0m48.0m38.0m27.5m27.1m17.9m11.5m9.6m39.7m

PP&E

86.0k80.0k102.0k221.0k208.0k374.0k396.0k338.0k309.0k280.0k236.0k219.0k200.0k105.0k83.0k655.8k
show all
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(3.3m)(21.4m)(28.5m)(30.0m)(20.7m)(15.0m)

Depreciation and Amortization

30.0k57.0k123.0k148.0k115.0k279.0k

Accounts Payable

955.0k1.3m1.1m4.2m(6.2m)(2.5m)

Cash From Operating Activities

(10.0m)(17.6m)(23.7m)(22.4m)(23.2m)(15.6m)
Quarterly
USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Net Income

(10.6m)(4.6m)(9.7m)(15.0m)(6.6m)(14.5m)(21.6m)(6.5m)(12.1m)(24.4m)(6.1m)(11.0m)(15.5m)(6.5m)(11.8m)(13.4m)(10.1m)

Depreciation and Amortization

21.0k8.0k17.0k33.0k24.0k52.0k87.0k40.0k77.0k115.0k32.0k61.0k83.0k174.0k196.0k279.0k49.8k

Accounts Payable

1.3m296.0k366.0k488.0k(367.0k)730.0k869.0k(2.1m)(942.0k)4.0m(220.0k)(7.0m)(6.7m)155.0k(1.0m)(1.5m)1.9m

Cash From Operating Activities

(7.9m)(3.9m)(8.5m)(12.4m)(5.9m)(11.5m)(18.1m)(7.4m)(10.7m)(16.7m)(5.5m)(15.8m)(18.9m)(5.1m)(11.0m)(12.5m)(7.1m)
show all
USDQ3, 2014

Financial Leverage

-0.2 x
Show all financial metrics

Proteon Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

80/100

Learn more about our premium products
SecurityScorecard logo

Proteon Therapeutics Online and Social Media Presence

Proteon Therapeutics's Trends

Embed Graph

Proteon Therapeutics News and Updates

October 31, 2019

Proteon Therapeutics Announces Third Quarter 2019 Financial Results

WALTHAM, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (“Proteon” or the “Company”) (Nasdaq: PRTO), a company that has historically focused on the development of novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular disease, t…
September 23, 2019

Proteon Therapeutics and ArTara Therapeutics Agree to Combine

Transaction to Create NASDAQ-Listed Rare and Specialty Disease Therapeutic Company Focused on Immunology and Metabolic Disorders
May 08, 2019

Proteon Therapeutics Announces First Quarter 2019 Financial Results

WALTHAM, Mass., May 08, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular diseases, today announced its financial results for the quarter ended March 31, 2…
March 04, 2019

Proteon Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference on March 11th

WALTHAM, Mass., March 04, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq: PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced that Company management will present at the Cowen and Com…
November 07, 2018

Proteon Therapeutics Announces Third Quarter 2018 Financial Results

WALTHAM, Mass., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced its financial results for the quarter ended September 30,…
August 07, 2018

Proteon Therapeutics Announces Second Quarter 2018 Financial Results

WALTHAM, Mass., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced its financial results for the quarter ended June 30, 2018,…

Proteon Therapeutics Blogs

August 07, 2019

Proteon Therapeutics Announces Second Quarter 2019 Financial Results

WALTHAM, Mass. , Aug. 07, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company that has historically focused on the development of novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular disease, today announced its financial
March 28, 2019

Proteon Therapeutics Announces Top-Line Results From Phase 3 PATENCY-2 Clinical Trial of Vonapanitase in Radiocephalic Arteriovenous Fistulas

- Investigational Vonapanitase Did Not Meet Co-Primary Endpoints - WALTHAM, Mass. , March 28, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today
March 13, 2019

Proteon Therapeutics Announces Fourth Quarter and Full-Year 2018 Financial Results

WALTHAM, Mass. , March 13, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular diseases, today announced its financial results for the year ended December 31,
January 24, 2019

Proteon Therapeutics Announces Publication of Results from Phase 3 PATENCY-1 Clinical Trial of Investigational Vonapanitase in Patients with Chronic Kidney Disease

Proteon Therapeutics Announces Publication of Results from Phase 3 PATENCY-1 Clinical Trial of Investigational Vonapanitase in Patients with Chronic Kidney Disease Content Import Thu, 01/24/2019 - 08:05 Proteon Therapeutics Announces Publication of Results from Phase 3 PATENCY-1 Clinical T…
January 17, 2019

Bradley Hartman

Bradley Hartman Justin.Howard@… Thu, 01/17/2019 - 12:42 Bradley Hartman Vice President, People Brad Hartman comes to Proteon with deep experience scaling biotech companies from early-stage research efforts through product commercialization, creating inclusive, eng…
November 08, 2018

Proteon Therapeutics to Present at the Stifel 2018 Healthcare Conference November 13th

WALTHAM, Mass. , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced that Company management will present at the Stifel 2018
Show more

 Proteon Therapeutics Frequently Asked Questions

  • When was Proteon Therapeutics founded?

    Proteon Therapeutics was founded in 2001.

  • Who are Proteon Therapeutics key executives?

    Proteon Therapeutics's key executives are Timothy Noyes and George Eldridge.

  • How many employees does Proteon Therapeutics have?

    Proteon Therapeutics has 17 employees.

  • Who are Proteon Therapeutics competitors?

    Competitors of Proteon Therapeutics include Biogen, MyoKardia and Athersys.

  • Where is Proteon Therapeutics headquarters?

    Proteon Therapeutics headquarters is located at 200 West St, Waltham.

  • Where are Proteon Therapeutics offices?

    Proteon Therapeutics has an office in Waltham.

  • How many offices does Proteon Therapeutics have?

    Proteon Therapeutics has 1 office.